59,259 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP purchased a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 59,259 shares of the company's stock, valued at approximately $825,000. GSA Capital Partners LLP owned about 0.06% of Day One Biopharmaceuticals as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. ProShare Advisors LLC lifted its stake in Day One Biopharmaceuticals by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 17,379 shares of the company's stock valued at $287,000 after buying an additional 1,447 shares in the last quarter. Altitude Crest Partners Inc. purchased a new stake in Day One Biopharmaceuticals during the 1st quarter worth about $3,230,000. Estuary Capital Management LP increased its position in Day One Biopharmaceuticals by 82.5% during the 1st quarter. Estuary Capital Management LP now owns 1,611,137 shares of the company's stock worth $26,616,000 after purchasing an additional 728,240 shares in the last quarter. Bayesian Capital Management LP acquired a new position in Day One Biopharmaceuticals in the 1st quarter valued at about $221,000. Finally, Janus Henderson Group PLC lifted its holdings in Day One Biopharmaceuticals by 19.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,032,384 shares of the company's stock valued at $33,575,000 after purchasing an additional 336,281 shares in the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total value of $426,600.00. Following the completion of the transaction, the insider now directly owns 1,097,535 shares in the company, valued at $15,606,947.70. The trade was a 2.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last three months, insiders have sold 51,745 shares of company stock valued at $775,867. Company insiders own 8.40% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DAWN. JPMorgan Chase & Co. cut their price objective on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an "overweight" rating for the company in a research report on Tuesday, August 6th. TD Cowen raised Day One Biopharmaceuticals to a "strong-buy" rating in a research report on Monday, November 4th. Bank of America upgraded Day One Biopharmaceuticals from an "underperform" rating to a "buy" rating and increased their target price for the stock from $11.00 to $24.00 in a research report on Thursday, August 1st. HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, Wedbush reaffirmed an "outperform" rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Day One Biopharmaceuticals has a consensus rating of "Buy" and a consensus price target of $35.71.

Day One Biopharmaceuticals Price Performance

DAWN opened at $13.31 on Friday. Day One Biopharmaceuticals, Inc. has a 1-year low of $11.30 and a 1-year high of $18.07. The company has a 50-day moving average of $14.42 and a 200-day moving average of $14.37.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.58. The firm had revenue of $93.76 million during the quarter, compared to the consensus estimate of $15.05 million. During the same quarter last year, the firm posted ($0.54) earnings per share. On average, sell-side analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.88 earnings per share for the current fiscal year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.